Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. The French ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

Great hopes rest on a product from the French-Austrian company Valneva. However, a vaccine from U.S. company Novavax, also based on proven technology, may reach more markets this winter.